translation agency

BBC News
OPTIME Therapeutics Announces Safety Results of Innovative Microbicide Cream For Prevention of HIV, and Other STDs

March 25, 2003
WASHINGTON, March 25 /PRNewswire/ -- At the Microbicides 2003 conference in Washington DC, OPTIME Therapeutics, Inc. announced pre-clinical safety data from their liposomal microbicide cream for the prevention of HIV and other sexually transmitted diseases (STDs). No differences were found in results from treated vs. untreated animals (Pig-tailed Macaques). In the laboratory, this product has demonstrated strong, broad-spectrum activity against a number of infectious agents, including HIV, HSV types 1 and 2, and N. gonorrhoeae.

The product has shown no detrimental effects to innate microflora and epithelial tissues. This study was performed by Dr. Dorothy Patton at the University of Washington in Seattle. Collaborators included Dr. Lisa Rohan at Magee Womens Research Institute, Pittsburgh, PA and with Dr. Charles Isaacs at the Institute for Basic Research in Developmental Disabilities, Staten Island, NY.

"These preliminary results are a positive step in the development of this important new product. Safety studies are critical for these types of products as even the slightest irritation to the epithelium of the vagina or rectum can leave the user more vulnerable to infections," says Dr. Hans Hofland, OPTIME's Director of Research. "These studies will be repeated to ensure the absolute safety of this product. After that, efficacy of the product will be determined by measuring the level of protection against a Chlamydia challenge, this summer. Chlamydia is the most prevalent STD in the US. These are the final steps before we can move this product into human clinical trials."

Approximately 12 million individuals in the United States are infected with STDs each year. Every 6 seconds a person is infected with HIV. Current prevention strategies to address this global epidemic have been only partially successful. The use of topical microbicides offers a new approach to the prevention of STDs, since the product can be self-administered prior to sexual intercourse. An ideal microbicide should be safe and prevent the transmission of STDs caused by a wide variety of pathogens, including bacterial infections such as Chlamydia trachomatis and Neisseria gonorrhoeae, and viral infections such as HIV, HPV, HSV.

OPTIME Therapeutics ( is a diversified biopharmaceutical company engaged in research, development, and commercialization of innovative products to treat localized diseases. OPTIME has developed a patented drug delivery technology based on the novel, topical use of liposomes (OPTISOMES(TM)) and a patented manufacturing technology (OPTIMIX(TM)) which allows for the consistent and cost-effective production of its products at commercial scale.

This release may contain forward-looking statements, which refer to future events. The Company's management believes that the future performance of the Company bears risks and uncertainties. The actual events and results may deviate considerably from the forward-looking statements contained in this release.

SOURCE OPTIME Therapeutics, Inc.

Web Site: